NCT07081646 2026-03-13
ALACRITY
Alexion Pharmaceuticals, Inc.
Phase 1/2 Recruiting
Clinical Trials
4 trialsNCT05145816 2026-02-17
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
University of Texas Southwestern Medical Center
Phase 1/2 Recruiting
NCT01864018 2025-07-24
Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis
Mayo Clinic
Phase 1/2 Completed
NCT06097832 2025-07-10
NEXICART-2
Nexcella Inc.
Phase 1/2 Recruiting